We are live on ! Find out more
MPLT

MapLight Therapeutics
MPLT

81 hedge funds and large institutions have $502M invested in MapLight Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 13

57% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 14

24% more capital invested

Capital invested by funds: $405M → $502M (+$97M)

13% more funds holding in top 10

Funds holding in top 10: 8 → 9 (+1)

9% more funds holding

Funds holding: 74 → 81 (+7)

7.37% more ownership

Funds ownership: 50.84% → 58.21% (+7.4%)

Holders
81
Holders Change
+7
Holders Change %
+9.46%
% of All Funds
1%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.11%
New
22
Increased
26
Reduced
13
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BOCH
Blue Owl Capital Holdings
New York
+$12.1M
2
ACM
ADAR1 Capital Management
Texas
+$6.71M
3
RCM
RA Capital Management
Massachusetts
+$4.44M
4
BlackRock
BlackRock
New York
+$4.37M
5
UBS Group
UBS Group
Switzerland
+$3.9M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$9.66M
2
JG
Jain Global
New York
-$5.76M
3
Citadel Advisors
Citadel Advisors
Florida
-$3.34M
4
Ameriprise
Ameriprise
Minnesota
-$1.17M
5
Lazard Asset Management
Lazard Asset Management
New York
-$1.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$74.9M – – –
FIS
2
FCPM III Services
Netherlands
$65.6M – – –
T. Rowe Price Investment Management
3
T. Rowe Price Investment Management
Maryland
$57M +$49.3K +2,757 +0.1%
Goldman Sachs
4
Goldman Sachs
New York
$40.6M +$1.03M +57,705 +3%
BlackRock
5
BlackRock
New York
$27.2M +$4.37M +244,217 +22%
BOCH
6
Blue Owl Capital Holdings
New York
$20.5M +$12.1M +678,871 +208%
NFGH
7
Nan Fung Group Holdings
Hong Kong
$19.7M – – –
5VM
8
5AM Venture Management
California
$19.3M – – –
S
9
Sanofi
France
$18.5M – – –
VCM
10
Vanguard Capital Management
Pennsylvania
$14.6M +$12.9M +719,820 New
PBPIA
11
Pivotal bioVenture Partners Investment Advisor
California
$12.4M – – –
VCIM
12
Velan Capital Investment Management
Georgia
$10M -$526K -29,412 -6%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$9.79M +$1.65M +92,175 +24%
SL
14
Siren LLC
Connecticut
$9.15M – – –
VPC
15
Vestal Point Capital
New York
$8.54M +$626K +35,000 +9%
ACM
16
ADAR1 Capital Management
Texas
$7.62M +$6.71M +374,909 New
BBA
17
Baker Bros. Advisors
New York
$7.41M – – –
State Street
18
State Street
Massachusetts
$6.89M +$1.96M +109,632 +48%
FGP
19
Freestone Grove Partners
California
$6.38M +$2.33M +130,186 +71%
BNP Paribas Asset Management
20
BNP Paribas Asset Management
France
$5.44M +$2.14M +119,816 +81%
RCM
21
RA Capital Management
Massachusetts
$5.05M +$4.44M +248,294 New
UBS Group
22
UBS Group
Switzerland
$4.81M +$3.9M +218,222 +1,193%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$4.16M +$3.64M +203,597 +22,522%
BOTOTLSJU
24
Board of Trustees of The Leland Stanford Junior University
California
$4.05M -$36 -2 -0%
SCM
25
Superstring Capital Management
New York
$3.91M +$3.44M +192,139 New
1
2 3 4

MPLT Hedge Fund Activity: Q1 2026 in Review

81 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in MapLight Therapeutics (MPLT) for Q1 2026, worth a combined $502M — up 24% from $405M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new MPLT positions and 14 closed out — a net gain of 8 holders — while 26 added to existing stakes and 13 trimmed.

The largest buyer was Blue Owl Capital Holdings, adding an estimated $12.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.66M sold.

  • 81 institutional investors held MapLight Therapeutics (MPLT) as of Q1 2026, up from 74 in Q4 2025.
  • Funds reported $502M of MapLight Therapeutics stock for Q1 2026, up 24% quarter-over-quarter.
  • 22 funds opened new MapLight Therapeutics positions in Q1 2026 and 14 closed out, a net change of +8 holders.
  • The largest MapLight Therapeutics buyer in Q1 2026 was Blue Owl Capital Holdings, an estimated $12.1M added.
  • The largest MapLight Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $9.66M sold.

Based on aggregated 13F filings for Q1 2026.